Targeted adalimumab treatment can optimize long-term outcomes for patients with early rheumatoid arthritis, study suggests

New research shows that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some.

Read the whole article on Science Daily

More from Science Daily